{"id":"W2139785591","doi":"10.1056/nejmoa1207541","title":"Apixaban for Extended Treatment of Venous Thromboembolism","year":2012,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":1341,"is_retracted":false,"has_abstract":true,"ca_institutions":"Thrombosis and Atherosclerosis Research Institute; McMaster University","funders":"Sanofi; Bayer HealthCare; GlaxoSmithKline; Pfizer; Daiichi Sankyo Europe; Bristol-Myers Squibb","keywords":"Apixaban; Venous thromboembolism; Medicine; Regimen; Intensive care medicine; Internal medicine; Atrial fibrillation; Rivaroxaban; Thrombosis; Warfarin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1024440574879457,"score_gpt":0.3778103075848138,"score_spread":0.2753662500968681,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}